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ABSTRACT The chronic impact of ambient air pollutants on lung function in adults is not fully
understood. The objective of this study was to investigate the association of long-term exposure to ambient
air pollution with lung function in adult participants from five cohorts in the European Study of Cohorts
for Air Pollution Effects (ESCAPE).
Residential exposure to nitrogen oxides (NO2, NOx) and particulate matter (PM) was modelled and
traffic indicators were assessed in a standardised manner. The spirometric parameters forced expiratory
volume in 1 s (FEV1) and forced vital capacity (FVC) from 7613 subjects were considered as outcomes.
Cohort-specific results were combined using meta-analysis.
We did not observe an association of air pollution with longitudinal change in lung function, but we
observed that a 10 μg·m−3 increase in NO2 exposure was associated with lower levels of FEV1 (−14.0 mL,
95% CI −25.8 to −2.1) and FVC (−14.9 mL, 95% CI −28.7 to −1.1). An increase of 10 μg·m−3 in PM10,
but not other PM metrics (PM2.5, coarse fraction of PM, PM absorbance), was associated with a lower
level of FEV1 (−44.6 mL, 95% CI −85.4 to −3.8) and FVC (−59.0 mL, 95% CI −112.3 to −5.6). The
associations were particularly strong in obese persons.
This study adds to the evidence for an adverse association of ambient air pollution with lung function
in adults at very low levels in Europe.
@ERSpublications
The ESCAPE study finds that, even at very low levels, air pollution has adverse effects on lung
function in adults http://ow.ly/A1ssB
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Introduction
Lung function, specifically forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1), are
objectively measurable quantitative parameters of respiratory health. It is an early indicator of respiratory
and systemic inflammation, and associated with cardiorespiratory morbidity and mortality. Acute effects of
air pollution on lung function at levels currently observed in Western Europe at all ages are well
established. To what extent long-term exposure to air pollution results in lower lung function remains less
clear [1]. Evidence for long-term pollution effects on slowing down lung function growth in children is
strong, while data for chronic lung function effects in adults is more limited and mostly restricted to
susceptible populations [1–3]. In the largest of the predominantly cross-sectional studies [4–7], FORBES
et al. [4] found increases in 10 μg·m−3 of particulate matter of size 10 μm or less (PM10) associated with a
decrease of about 3% in FEV1. At first spirometry SAPALDIA found an increase of 10 μg·m−3 in annual
mean concentration of PM10 was associated with 3.4% lower FVC and 1.6% lower FEV1 [5]. The SALIA
study of females showed negative associations of PM10 concentrations with FEV1 and FVC (5.1% and
3.7% respectively, per 7 μg·m−3 5-year annual mean PM10) [7]. The strongest indirect evidence for adverse
long-term pollution effects on lung function decline in adults comes from a single follow-up study
demonstrating that improvements in PM10 exposure over a period of 11 years attenuated the age-related
decrease in respiratory function [8]. A more recent study found cumulative long-term exposure to ambient
PM10 and ozone associated with both FEV1 and FVC decline in an elderly population and suggested an
increased susceptibility among frail persons [9]. Statistically significant associations were also reported for
NO2 and traffic exposure [5, 7].
The ESCAPE project (European Study of Cohorts for Air Pollution Effects) combined data from over 30
cohort studies and modelled home outdoor levels of air pollution in a standardised manner [10]. This
paper makes use of five health cohorts with spirometry data, to investigate the association of air pollution
with lung function level and age-related decline.
Methods
Design and participants
This study is an analysis of cohort data obtained by ESCAPE to investigate the long term effects of
exposure to air pollution on respiratory health in Europe and a meta-analysis of the cohort specific results.
The present study included five European cohorts/studies from eight countries with information on lung
function and the most important potential confounders. The analyses were based on subpopulations from
the European Community Respiratory Health Survey (ECRHS), French Epidemiological study on Genetics
and Environment of Asthma (EGEA), the National Survey of Health and Development (NSHD), Study on
the influence of Air pollution on Lung function, Inflammation and Aging (SALIA) and Swiss Cohort
Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA) (online supplementary
material (methods: cohorts section) and supplementary table S1). Criteria for inclusion of cohort
participants in the present analyses were: age of at least 20 years; pre-bronchodilation spirometry data
from two different time points approximately one decade apart (referred to as first and second spirometry,
respectively); non-missing information for the primary covariates used in the main models
(questionnaire-based variables: age, sex, smoking status, education; measured variables: height and BMI
(derived from measured height and weight)); living in cohort areas selected for ESCAPE monitoring
campaigns; and successfully assigned home outdoor exposure estimates for NO2/NOx/traffic indicators
(referred to as NO-population) and PM metrics (a subsample of the NO population, referred to as
PM-population). Of 13 259 participants with first and second spirometry living in ESCAPE monitoring
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areas, 7615 and 4233, respectively provided complete datasets towards analysis of NO2/NOx/traffic
indicators and PM metrics (supplementary figure S1). All included cohort studies were approved by the
institutional medical ethics committees and undertaken in accordance with the Declaration of Helsinki.
Each cohort study followed the rules for ethics and data protection set up in the country in which they
were based.
Exposure data
ESCAPE exposure assessment has been described previously, and is based on fully standardised
measurement and modelling protocols (www.escapeproject.eu/manuals/) [10–13]. The general concept
consisted in the individual assignment of outdoor annual mean concentrations of a pre-defined set of air
pollution markers to each participant’s residential address.
ESCAPE monitoring campaigns in different study areas between 2008 and 2011 measured NO2 and NOx
as well as, in a smaller number of areas PM2.5, PM10, the coarse fraction of PM (PM10 minus PM2.5) and
light absorbance of PM2.5. Within each study area, concentration levels were monitored at 40 (NO2, NOx)
or 20 (PM measures) predefined sites during three seasonally distinct 2-week periods [13, 14]. Land use
regression (LUR) models were developed to explain the spatial variation of measured annual average air
pollutant concentration within each study area. This technique combines measurement data with
Geographic Information System (GIS) derived land-use and traffic information to predict annual pollution
concentration at sites without measurements and was used to estimate annual pollutant concentrations at
each participant’s residential address [10, 11].
In addition to pollutant concentrations, we also used as indicators of local exposure to traffic related
pollutants, traffic intensity at the road nearest to a participant’s home and total traffic load on major roads
in a 100-m buffer of the home. Traffic measures were often used in other studies as proxies of exposure to
near-road pollutants, such as ultrafine particles or NO, which exponentially decay within 100–150 m from
the curb side.
To address the time discrepancy between air pollution monitoring (2008–2011) and health examination
(spirometry conducted between 1985–2010; supplementary table S2), sensitivity analyses replaced ESCAPE
exposure estimates with estimates back extrapolated to the time of first and second spirometry (except for
the time of first spirometry in ECRHS and EGEA, where no historical data was available, and of second
spirometry in NSHD and SALIA conducted between 2006 and 2010, sufficiently close to the ESCAPE
monitoring campaigns). During the past decades, air quality has in general improved. Given the lack of
historic LUR models, ESCAPE could not individually estimate within-city contrasts of air quality for these
past years. Instead, where available, annual means from fixed site monitoring stations were used to derive
past annual mean concentrations for pollutants with available historic data (NO2 and PM10 only). For
each study participant’s home address the back extrapolated concentration was obtained by multiplying
the modelled ESCAPE annual mean concentration with the ratio between average annual concentrations as
derived from the routine monitoring site(s) for the period in the past and for the ESCAPE measurement
period time (details can be found in www.escapeproject.eu/manuals/) [12]. The procedures applied
assumed that the within-city spatial contrasts remained proportional over time. GULLIVER et al. [15]
confirmed the validity of this assumption for the UK.
Lung function metrics and outcomes
FEV1 and FVC were used as outcome metrics. In cross-sectional analysis, we focused on lung function
measured at the second spirometry (time point closest to ESCAPE air pollution monitoring). Change in
lung function between first and second spirometry was assessed as both annual lung function change
(mL·year−1) and annual change in lung function as a percentage of the first spirometry value (%·year−1)
(supplementary material; methods: lung function metrics and outcomes section), with a negative value
representing a decline. Data presented are restricted to absolute change as results did not materially differ
for percent change as outcome.
Statistical analyses
First, study specific data were analysed separately following identical analytical procedures. Associations of
air pollutants with lung function metrics were estimated using multivariable mixed linear regression
models with a random intercept for ESCAPE areas with their own exposure monitoring and modelling.
Three confounder models were specified a priori, adjusting for an increasing number of covariates selected
on the basis of previous cohort studies of air pollution and lung function and the availability of data for
most cohorts, excluding missing values on any of the covariates. The covariate definitions were
standardised across studies (supplementary material; methods section). In the absence of materially
different effect estimates derived from models adjusting for additional covariates, we chose as main
40 DOI: 10.1183/09031936.00130014
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analytic model the one adjusting for age (years), age squared, height (cm), sex, body mass index (BMI;
kg·m−2), educational level (low as reference, medium, high), and smoking status (never as reference, ever).
Models analysing traffic exposure indices were additionally adjusting for background NO2 concentrations.
The traffic indicator coefficients are thus assumed to reflect the impact of pollutants highly concentrated
along the roads. The median of traffic indicator values across all studies was chosen as cut-off for
dichotomising the continuous traffic exposure (⩽5000 and >5000 cars per day for traffic intensity on the
nearest major road; ⩽500 and >500 car-km driven per day for the traffic intensity on major roads in a
100 m buffer) (supplementary material; methods: statistic models section). Traffic variables were also
analysed on a continuous scale but this did not produce meaningful results.
Secondly, cohort-specific overall and stratum-specific effect estimates obtained by mixed linear regression
models were meta-analysed (supplementary material; methods: meta-analysis section).
A pre-defined set of variables considering previous evidence and cohort differences was tested for effect
modification. We compared the summary estimates of the two opposite subgroups (females versus males;
not obese versus obese; never versus ever smokers; never asthma versus ever asthma) using a chi-square test
with one degree of freedom. In sensitivity analyses we restricted the analytical model to non-movers and
participants aged ⩾30 years (age at first spirometry).
A standardised analytical approach was used to minimise the possibility of differential bias across
participating cohorts. We controlled for different known or potential individual confounding factors in our
analyses. Moreover, we included random effects for the different cohort areas to adjust for geographic
clustering of outcomes. Additionally, we performed several sensitivity analyses in selected subsamples to
address specific potential biases (e.g. in the subsample of non-movers to address potential bias due to
health-related changes in exposure).
Statistical analyses were performed using STATA, version 12 (Stata Statistical Software, Release 12;
StataCorp., College Station, TX, USA).
Results
Study characteristics
Table 1 provides a description of the cohort specific study populations. The average age of the cohorts at
the time of second spirometry ranged from 43 years (ECRHS) to 73 years (SALIA). The SALIA
population, consisting exclusively of females, exhibited the lowest mean levels of FEV1 (2.20 L) and FVC
(2.91 L) (table 1) (for the smaller PM subpopulation and for the cohort-specific lung function
distributions stratified by sex, smoking and asthma status, refer to supplementary table S3).
Air pollution exposure
Table 2 shows the distribution of the air pollution metrics for each study area. Variance explained by LUR
models varied between 55% and 92% for NO2 and between 68% and 90% for PM10 (supplementary table
S4). Mean exposure was lowest for all air pollution metrics in NSHD. Within-study contrasts were smallest
for SALIA and SAPALDIA, reflecting the restricted geographic region covered (supplementary table S5).
The study specific correlations between the exposure metrics were generally highest between NO2 and NOx
(rho of 0.90–0.98), but moderate to low between pollutants and traffic indicators (supplementary table S6).
ESCAPE derived exposures were highly correlated with the exposures back-extrapolated to the time of the
second spirometry (rho(NO2) ⩾ 0.94; rho(PM10) ⩾0.91), but less strongly correlated with exposures
back-extrapolated to the first spirometry (0.56⩽ rho(NO2)⩽ 0.92; 0.47⩽ rho(PM10)⩽ 0.74).
Association between air pollution and lung function
The main meta-analysis results for associations of each air pollution metric with level and change of lung
function are presented in table 3. No associations between any exposure metric and lung function decline
were present, irrespective of covariate adjustment and subgroup (sex, obesity, asthma and smoking).
Looking at levels of lung function cross-sectionally, we found higher NO2 and NOx exposures to be
associated with lower levels of FVC and FEV1. An increase of 10 μg·m−3 in NO2 exposure was associated
with a −14.0 mL lower level of FEV1 (95% CI −25.8– −2.1) and −14.9 mL lower level of FVC (95% CI
−28.7– −1.1) (table 3, figs 1 and 2). An increase of 20 μg·m−3 in NOx exposure was associated with a
lower level of FEV1, by −12.9 mL (95% CI −23.87– −2.0) and of FVC, by −13.3 mL (95% CI −25.9–
−0.7) and an increase of 10 μg·m−3 in PM10 was associated with a lower level of FEV1 (−44.6 mL, 95% CI
−85.4– −3.8) and FVC (−59.0 mL, 95% CI −112.3– −5.7) (table 3). The other PM metrics were not
associated with lung function level. Higher traffic load on major roads in a 100 m buffer from residential
address was associated with lower levels of FEV1 (−32.34 mL, 95% CI −59.30– −5.38).
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TABLE 1 Description of cohort-specific study populations
ECRHS EGEA NSHD SALIA SAPALDIA
Total n 3859 568 844 580 1764
First spirometry 1991–1993 1991–1995 1999 1985–1994 1991–1992
Second spirometry 2001–2002 2003–2007 2006–2010 2007–2009 2002
Female 1981 (51.3) 303 (53.3) 471 (55.8) 580 (100.0) 980 (55.6)
Age years 43.0±7.2 53.1±11.3 63.3±1.1 73.3±3.4 53.2±11.0
BMI kg·m−2 25.7±4.6 25.3±4.3 27.7±4.9 27.4±4.5 25.4±4.3
Height cm 168.6±9.5 168.5±8.4 167.4±8.6 162.3±5.5 168.8±9.0
Ex-smoker 1064 (27.6) 206 (36.3) 497 (58.9) 99 (17.1) 568 (32.2)
Current smoker 1224 (31.7) 81 (14.3) 77 (9.1) 18 (3.1) 492 (27.9)
Pack years at first spirometry# 7.7±12.0 5.9±10.0 9.1±12.6 2.8±8.4 10.9±17.9
Pack years from first to second
spirometry#
3.9±10.9 1.7±8.3 0.7±2.5 0.6±6.7 3.1±6.5
Medium educational level# 1321 (34.2) 118 (20.8) 439 (52.0) 276 (47.6) 1121 (63.5)
High educational level# 1420 (36.8) 263 (46.3) 102 (12.1) 199 (34.3) 520 (29.5)
Environmental tobacco exposure at
home or at work#
676 (17.5) 233 (41.0) 168 (19.9) 347 (59.8) 119 (6.7)
Occupational exposure to
dust/fumes or gases#
1685 (43.7) 125 (22.0) 246 (29.1) 39 (6.7) 460 (26.1)
Ever asthma#,¶ 616 (16.0) 183 (32.2) 83 (9.8) 50 (8.6) 155 (8.8)
FEV1 L 3.47±0.81 3.03±0.85 2.83±0.66 2.20±0.42 3.10±0.82
FVC L 4.33±1.00 4.00±1.01 3.57±0.81 2.91±0.54 4.08±1.02
FEV1 change+ L −0.026±0.032 −0.028±0.031 −0.022±0.025 −0.020±0.014 −0.033±0.030
FVC change+ L −0.018±0.040 −0.015±0.037 −0.025±0.034 −0.022±0.019 −0.022±0.041
Data are presented as mean±SD for continuous variables, or n (%) for categorical variables, unless otherwise stated. Characteristics refer to
time point of second spirometry, and are presented for the larger subgroup of participants included in the analysis of NO2 and NOx and traffic
indicators (characteristics for the smaller subgroup of participants included in the particulate matter metrics analyses are presented in
supplementary table S1). BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity. #: information missing on a
limited number of subjects; ¶: asthma diagnosed by a physician at first and/or at second spirometry; +: change in lung function between first
and second spirometry.
TABLE 2 Distribution of all exposure estimates (annual averages of ambient air pollutants and traffic indicators), at participants
residential addresses in each cohort
Exposures ECRHS EGEA NSHD SALIA SAPALDIA
N Mean IQR N Mean IQR N Mean IQR N Mean IQR N Mean IQR
PM2.5 μg·m−3 1830 15.9 7.0 342 15.3 2.0 751 9.5 1.5 580 17.8 1.7 729 16.8 1.1
PM2.5 absorbance ×10−5 m−1 1540 2.0 1.6 148 2.1 1.3 751 1.0 0.3 580 1.4 0.4 729 1.9 0.5
PM10 μg·m−3 1830 25.8 9.7 342 25.1 4.0 751 15.7 1.9 580 26.7 2.1 729 23.2 2.3
Coarse PM# μg·m−3 1830 10.3 4.7 342 9.4 3.3 751 6.4 0.8 580 9.4 1.6 729 6.5 1.9
NO2 μg·m
−3 3859 28.9 18.7 568 27.4 14.7 844 22.4 10.0 580 27.6 8.1 1764 27.0 7.7
NOx μg·m
−3 3859 50.5 34.5 568 46.7 27.9 844 37.5 17.1 580 44.2 20.7 1764 44.8 15.2
Traffic intensity on nearest road¶ 2492 4807 5509 568 6633 6667 844 1239 0 580 1642 0 1697 3207 3876
Traffic load on nearest major
road+
2687 1.45 1.67 568 1.37 1.58 844 0.27 0 580 0.72 0.32 1671 0.94 1.42
NO2 back-extrapolated to first
spirometry μg·m−3
NA§ NA§ NA§ NA§ NA§ NA§ 841 26.3 11.2 580 36.0 14.0 1762 47.7 12.3
PM10 back-extrapolated to first
spirometry μg·m−3
NA§ NA§ NA§ NA§ NA§ NA§ 748 22.0 2.6 580 47.7 13.6 726 46.2 4.0
NO2 back-extrapolated to second
spirometry μg·m−3
3859 34.2 23.0 568 32.1 17.5 NAƒ NAƒ NAƒ NAƒ NAƒ NAƒ 1764 31.0 8.0
PM10 back-extrapolated to
second spirometry μg·m−3
1388 27.1 8.4 148 27.0 5.3 NAƒ NAƒ NAƒ NAƒ NAƒ NAƒ 729 37.8 4.3
IQR: interquartile range; PM2.5: particulate matter with a diameter of ⩽2.5 μm; PM10: particulate matter with a diameter of ⩽10 μm. #: fraction
of PM2.5 to relative to PM10; ¶: cars per day; +: traffic load on nearest major road within a 100 m buffer presented in thousands of car-km
driven per day; §: no complete exposure back-extrapolation to first spirometry available; ƒ: no back-extrapolation applied as time point of
second spirometry coincides with time point of ESCAPE monitoring campaign.
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Associations observed for NO2 and PM10 with FEV1 and FVC at second spirometry remained largely
unaltered when ESCAPE exposure estimates of NO2 and PM10 in ECRHS, EGEA and SAPALDIA were
replaced with NO2 and PM10 estimates back-extrapolated to the time point of the second spirometry. The
inverse association between PM10 and FVC became stronger and statistically significant (supplementary
table S7).
In subgroup analysis, the NO2 and NOx (data not shown) associations with FEV1 and FVC were
particularly observed in obese participants (FEV1: figures 3 and 4; FVC: supplementary figures S2 and S3)
(p-values for heterogeneity, obese versus non-obese: p=0.098 for NO2/FEV1 (figures 3 and 4); p=0.026 for
NO2/FVC (supplementary figures S2 and S3); p=0.050 for NOx/FVC). All other tested factors (sex,
smoking and asthma status) showed no or only weak evidence for modification of the air pollution lung
function associations (NO2: supplementary table S8). The effect modification by obesity was also evident
in sex-stratified analyses, with substantially stronger inverse NO2 and NOx associations with FEV1 and
FVC, in both obese females and males (NO2: supplementary table S9).
In sensitivity analysis, looking at non-movers and participants aged 30 years or more, we did not find a
particular difference from the observed main associations (supplementary table S10).
Discussion
This study in adults contributes to the evidence of long-term exposure to ambient air pollution being
associated with the level of lung function. The meta-analysis was based on individual-level exposure
assessment standardised across different cities and regions in Europe. Impaired lung function characterised
by reduced FEV1, a powerful marker of future morbidity and mortality [16], exhibited the most consistent
association with different pollution metrics. It was inversely related to nitrogen oxides and PM10, as well as
to traffic load at the residential address. Our data suggest that obese persons are particularly sensitive to
air pollution.
Comparison with other studies
Results from previous cross-sectional studies predominantly relied on exposure measured at the level of a
few communities. They point to an inverse association of adult lung function with air pollution and traffic
load [1, 6], but as the measurement and meaning of specific pollution metrics differs between studies their
comparative relevance remains inconclusive. This also applies to the current study. According to the
site-specific differences in correlations between exposure metrics (supplementary table S6) they capture
different sources of air pollution and thereby different components. The absence of associations with most
of the PM metrics may additionally be rooted in the more limited sample size. PM measurements were
only performed in a limited number of centres. NO2, which characterises the spatial variation of traffic
related air pollution, has been linked with stronger lung function impairment depending on the parameter
studied, but evidence that PM effects are stronger has also been published [3, 7].
The interaction between air pollution exposure and obesity on lung function parallels a recent SAPALDIA
report and adds evidence to the interdependence of the two important global epidemics of environmental
pollution and obesity [17]. Many studies have demonstrated an association between obesity and lung
function. Lung function improves after weight loss in obese persons, and weight gain is associated with lung
function decline in asthmatics and in the general population [17–19]. The mechanical effect of excess body
fat on lung volumes and airway calibre is well accepted [18]. In addition, inflammatory pathways may play a
role, as overweight is associated with an underlying state of oxidative stress and inflammation [17, 20]. Air
pollution and obesity seemingly have more than additive effects on systemic inflammation [21, 22]. In animal
models, ozone-induced pulmonary injury and inflammation were greater in obese versus lean mice [23, 24].
In humans, acute ozone effects on lung function were more prominent among obese subjects [25, 26].
The null finding investigating the association of air pollution with the change in lung function is
consistent with a previous report from the ECRHS cohort [27], but extends the finding to older cohorts.
In light of the positive findings for the cross-sectional associations, this null finding may be surprising.
Cross-sectional differences are expected to result at least in part from differences in age-related decline.
Based on the current results it seems premature to conclude that long-term exposure to air pollution does
not affect FEV1 and FVC decline.
Strengths and weaknesses
Our study benefits from a large number of observations, and the multicentre design across different
European regions, covering a broad range of different types of environment and climates and a wide age
range of participants. Furthermore, the individual-level exposure assessment was harmonised, a common
study protocol of exposure and outcome definition was developed and the analytic approach was
standardised. However, this study has also several limitations.
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Several methodological issues related to outcome and exposure assessment may have biased the
longitudinal association. Data from only two spirometry time points and from spirometries conducted in
different seasons and times of the day may have decreased the precision in estimating lung function
decline. As common in long-term lung function studies, spirometry devices had to be updated with new
software or replaced during follow-up. Such changes can be an inherent source of differences in the
measured lung function and its temporal change [28]. The inherent limitations in exposure assessment are
TABLE 3 Results of meta-analyses for the association between level and change of lung function and exposure to air pollution
and traffic intensity indicators
Exposure (increment) Level of lung function (mL)#
FEV1 FVC
Beta¶ 95% CI I2 §
p-value (het)
Beta¶ 95% CI I2 §
p-value (het)
NO2 (10 μg·m
−3) −13.98 −25.82 to −2.14 0.0%
p=0.625
−14.93 −28.73 to −1.13 0.0%
p=0.977
NOx (20 μg·m
−3) −12.91 −23.79 to −2.04 0.0%
p=0.861
−13.25 −25.85 to −0.65 0.0%
p=0.962
PM10 (10 μg·m−3) −44.56 −85.36 to −3.76 0.0%
p=0.628
−58.96 −112.27 to −5.65 0.0%
p=0.785
PM2.5 (5 μg·m−3) −21.14 −56.37 to 14.08 0.0%
p=0.535
−36.39 −83.29 to 10.50 0.0%
p=0.877
PM2.5 absorbance (1×10−5 m−1) −24.40 −55.58 to 6.79 0.0%
p=0.709
−12.94 −50.23 to 24.30 0.0%
p=0.619
Coarse PM (5 μg·m−3) −22.36 −94.00 to 49.27 12.6%
p=0.333
2.88 −87.85 to 93.60 0.0%
p=0.760
Traffic intensity on nearest road
(high/low)ƒ,##
−27.61 −59.62 to 4.39 29.0%
p=0.228
−10.37 −48.23 to 27.49 27.3%
p=0.239
Traffic load on nearest major road
in a 100-m buffer (high/low)##,¶¶
−32.34 −59.30 to −5.38 0.0%
p=0.784
−18.64 −50.22 to 12.94 0.0%
p=0.967
Exposure (increment) Change in lung function (mL per year)
FEV1 FVC
Beta§§ 95% CI I2 §
p-value (het)
Beta§§ 95% CI I2 §
p-value (het)
NO2 (10 μg·m
−3) 0.30 −0.39 to 0.98 0.0%
p=0.681
0.02 −0.84 to 0.88 0.0%
p=0.532
NOx (20 μg·m
−3) 0.18 −0.44 to 0.80 0.0%
p=0.708
−0.09 −0.86 to 0.69 0.0%
p=0.804
PM10 (10 μg·m−3) −0.39 −2.85 to 2.06 53.1%
p=0.074%
−1.42 −4.53 to 1.70 28.4%
p=0.232
PM2.5 (5 μg·m−3) −0.14 −2.26 to 1.98 23.8%
p=0.263
−1.37 −4.04 to 1.29 0.0%
p=0.964
PM2.5 absorbance (1×10−5 m−1) 0.88 −0.76 to 2.52 54.5%
p=0.066
1.14 −0.95 to 3.24 4.5%
p=0.381
Coarse PM (5 μg·m−3) 0.26 −3.92 to 4.43 61.7%
p=0.034
−1.31 −6.49 to 3.88 0.0%
p=0.506
Traffic intensity on nearest road
(high/low)ƒ,##
−0.74 −2.58 to 1.10 0.0%
p=0.772
−0.15 −2.49 to 2.18 18.1%
p=0.299
Traffic load on nearest major road
in a 100-m buffer (high/low)##,¶¶
−0.32 −1.81 to 1.18 0.0%
p=0.987
0.34 −1.56 to 2.25 0.0%
p=0.672
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; PM: particulate matter. #: level of lung function for cross-sectional analysis
was derived from second spirometry. ¶: the beta values for the association between level of lung function and exposure are adjusted for age,
age squared, height, sex, body mass index (BMI), highest educational level, and smoking status at second spirometry; a negative sign indicates
lower lung function with increasing exposure. §: I2 and Cochran’s test for heterogeneity of effect estimates between cohorts. ƒ: low traffic
intensity on nearest road: ⩽5000 cars per day; high: >5000 cars per day. ##: associations with traffic intensity (high/low) and traffic load (high/
low) were additionally adjusted for background NO2 concentrations.
¶¶: low traffic load on the nearest major road in a 100-m buffer: ⩽500
car-km driven per day; high: >500 car-km driven per day. §§: the beta values of the association between change in lung function and exposure
are adjusted for sex, age and height at first spirometry, highest educational level, smoking at first spirometry, smoking cessation and change in
BMI to the second spirometry; a negative sign indicates steeper lung function decline with increasing exposure.
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I-V subtotal (I-squared=0.0%, p=0.625)
EGEA
SALIA
NSHD
D+L subtotal
ECRHS
SAPALDIA
NO2_1
-13.98 (-25.82– -2.14)
4.52 (-38.28–47.32)
-22.97 (-63.06–17.12)
-19.86 (-59.26–19.55)
-13.98 (-25.82– -2.14)
-18.22 (-33.33– -3.12)
5.09 (-27.56–37.75)
100.00
7.65
8.72
9.03
61.46
13.14
568
580
842
3859
1764
Study ES (95% CI) N(I-V)
Weight %
FEV1 (all) by NO2
Increased risk
Coefficient
Decreased risk
-63.1 0 63.1
FIGURE 1 Forest plot displaying the study-specific mixed linear regression model estimates of the association of NO2
with level of forced expiratory volume in 1 s (FEV1; in mL) (based on all study participants living in sites with ESCAPE
models available). NO2_1 indicates NO2 measured at time of ESCAPE. Associations with lung function measures are
presented as increments in NO2 per 10 μg·m
−3. I-square: variation in estimated effects attributable to heterogeneity.
D+L (Der Simonian and Laird method): pooled estimate of all studies. The mixed linear regression models were
adjusted for: age, age squared, height, sex, body mass index, highest educational level, and smoking status at second
spirometry; negative estimates indicated lower lung function with increasing exposure. ES: effect size.
I-V subtotal (I-squared=0.0%, p=0.977)
EGEA
SALIA
NSHD
D+L subtotal
ECRHS
SAPALDIA
NO2_1
-14.93 (-28.73– -1.13)
-14.93 (-28.73– -1.13)
-1.78 (-46.41–42.84)
-20.79 (-70.20–28.63)
-10.69 (-56.63–35.25)
-16.40 (-34.00–1.21)
-17.25 (-56.79–22.30)
100.00
9.56
7.80
9.02
61.45
12.18
568
580
842
3859
1764
Study ES (95% CI) N(I-V)
Weight %
FVC (all) by NO2
Increased risk
Coefficient
Decreased risk
-70.2 0 70.2
FIGURE 2 Forest plot displaying the study-specific mixed linear regression model estimates of the association of NO2
with level of forced vital capacity FVC; in mL) (based on all study participants living in sites with ESCAPE models
available). NO2_1 indicates NO2 measured at time of ESCAPE. Associations with lung function measures are presented
as increments in NO2 per 10 μg·m
−3. I-square: variation in estimated effects attributable to heterogeneity. D+L (Der
Simonian and Laird method): pooled estimate of all studies. The mixed linear regression models were adjusted for: age,
age squared, height, sex, body mass index, highest educational level, and smoking status at second spirometry; negative
estimates indicated lower lung function with increasing exposure. ES: effect size.
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I-V subtotal (I-squared=12.7%, p=0.333)
EGEA
SALIA
NSHD
D+L subtotal
ECRHS
SAPALDIA
NO2_1
-8.18 (-21.01–4.66)
16.20 (-28.88–61.27)
-26.19 (-76.64–24.26)
-4.10 (-51.77–43.57)
-6.29 (-21.55–8.97)
-15.47 (-31.48–0.54)
17.49 (-16.86–51.84)
100.00
8.10
6.47
7.25
64.23
13.95
495
409
587
3279
1512
Study ES (95% CI) N(I-V)
Weight %
FEV1 (not obese) by NO2
Increased risk
Coefficient
Decreased risk
-76.6 0 76.6
FIGURE 3 Forest plot displaying the study-specific mixed linear regression model estimates of the association of NO2
with level of forced expiratory volume in 1 s (FEV1; in mL) in participants stratified as not obese (body mass index
(BMI) <30 kg·m−2). NO2_1 indicates NO2 measured at time of ESCAPE. Associations with lung function measures are
presented as increments in NO2 per 10 μg·m
−3. I-square: variation in estimated effects attributable to heterogeneity.
D+L (Der Simonian and Laird method): pooled estimate of all studies. The mixed linear regression models were
adjusted for: age, age squared, height, sex, BMI, highest educational level, and smoking status at second spirometry;
negative estimates indicated lower lung function with increasing exposure. p-value for heterogeneity, obese versus
non-obese: 0.098 for FEV1. ES: effect size.
I-V subtotal (I-squared=0.0%, p=0.907)
EGEA
SALIA
NSHD
D+L subtotal
ECRHS
SAPALDIA
NO2_1
-32.74 (-58.84– -6.65)
-32.74 (-58.84– -6.65)
-17.39 (-180.11–145.33)
-14.08 (-79.11–50.95)
-46.88 (-115.76–22.00)
-31.08 (-64.61–2.44)
-69.82 (-172.91–33.26)
100.00
2.57
16.10
14.35
60.57
6.41
73
171
255
580
262
Study ES (95% CI) N(I-V)
Weight %
FEV1 (obese) by NO2
Increased risk
Coefficient
Decreased risk
-180 0 180
FIGURE 4 Forest plot displaying the study-specific mixed linear regression model estimates of the association of NO2
with level of forced expiratory volume in 1 s (FEV1; in mL) in obese participants (body mass index (BMI) ⩾30 kg·m−2).
NO2_1 indicates NO2 measured at time of ESCAPE. Associations with lung function measures are presented as
increments in NO2 per 10 μg·m
−3. I-square: variation in estimated effects attributable to heterogeneity. D+L (Der
Simonian and Laird method): pooled estimate of all studies. The mixed linear regression models were adjusted for: age,
age squared, height, sex, BMI, highest educational level, and smoking status at second spirometry; negative estimates
indicated lower lung function with increasing exposure. p-value for heterogeneity, obese versus non-obese: 0.098 for
FEV1. ES: effect size.
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also amplified in the longitudinal analyses. Most importantly, back-extrapolation of residential pollution
levels is of prime relevance to properly characterise exposure at first spirometry, and then derive the
change in exposure over time. Uncertainties with the back-extrapolated values may be substantial and if
unrelated to the true exposure, may bias findings towards the null. In addition LUR models have inherent
limitations. Cross-validation of the LURs varied across regions [10, 11] and performance of models based
on 20 or 40 measurement sites may be overestimated [29, 30].
Additional limitations of the study beyond back-extrapolation include the non-availability of information
on short-term exposure at the time of spirometry for a sufficient number of sites and pollution metrics.
Adjustment for short-term exposure in SAPALDIA did not alter the associations. Heterogeneity of study
populations poses a challenge to meta-analysis and makes it difficult to exclude residual confounding and
unrecognised effect modification. The associations were not sensitive to the SALIA study consisting
exclusively of females and exhibiting the lowest mean levels of lung function (supplementary figures S4
and S5 for associations of NO2 with FEV1 and FVC in females). Non-participation at follow-up of subjects
with low lung function may bias observed associations or limit their generalisability. In SAPALDIA,
subjects with better lung function were more likely to participate in the second spirometry, but sensitivity
analyses using inverse probability weighting to account for non-participation did not alter associations
between air pollution and lung function [8].
Conclusion
The current study, which includes a large number of observations from different regions, environments
and climates in Europe, and standardized exposure assessment, provides firm support to an adverse
association between ambient air pollution and lung function in adults. Inverse associations could be
observed at very low air pollution levels in Europe. The policy relevance of these findings is further
strengthened by the observation that obese persons may be particularly susceptible.
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